Drug Trial Radar · NCT06282159
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Actual
Start
Feb 23, 2024
Primary completion
Jul 28, 2025
Study completion Oct 2028
Sponsor
- Lead sponsor
- Dianthus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
Conditions
- Myasthenia Gravis, Generalized
Interventions
ClaseprubartDrug
Day 1: IV loading dose Week 1 to Week 11: Claseprubart administered SC every 2 weeks
PlaceboDrug
Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)Time frame: Baseline (Day 1) to Week 13
Locations
56 sites in 14 countries. Site status is shown where the registry gives one.
Clinical Study Site
Phoenix, Arizona
Clinical Study Site
Irvine, California
Clinical Study Site
Stamford, Connecticut
Clinical Study Site
Boca Raton, Florida
Clinical Study Site
Bradenton, Florida
Clinical Study Site
Maitland, Florida
Clincal Study Site
Tampa, Florida
Clinical Study Site
O'Fallon, Illinois
Clinical Study Site
Kansas City, Kansas
Clinical Study Site
Lexington, Kentucky
Clinical Study Site
Boston, Massachusetts
Clinical Study Site
East Lansing, Michigan
Clinical Study Site
Columbia, Missouri
Clinical Study Site
Cincinnati, Ohio
Clinical Study Site
Columbus, Ohio
Clinical Study Site
Dallas, Texas
Clinical Study Site
Dallas, Texas
Clinical Study Site #2
Houston, Texas
Clinical Study Site
Houston, Texas
Clinical Study Site
Lubbock, Texas
Clinical Study Site
Richmond, Virginia
Clinical Study Site
Buenos Aires, Argentina
Clinical Study Site
Buenos Aires, Argentina
Clinical Study Site
Buenos Aires, Argentina
Clinical Study Site
Córdoba, Argentina
Clinical Study Site
Rosario, Argentina
Clinical Study Site
San Miguel de Tucumán, Tucumán Province, Argentina
Clinical Study Site
London, Ontario, Canada
Clinical Study Site
Ostrava, Czechia
Clinical Study Site
Copenhagen, Denmark
Clinical Study Site
Bordeaux, France
Clinical Study Site
Nice, France
Clinical Study Site
Strasbourg, France
Clinical Study Site
Haifa, Israel
Clinical Study Site
Ramat Gan, Israel
Clinical Study Site
Safed, Israel
Clinical Study Site
Milan, Italy
Clinical Study Site
Naples, Italy
Clinical Study Site
Pisa, Italy
Clinical Study Site
Rome, Italy
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.